Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors Biostatistics Research Center (U01 Clinical Trial Not Allowed)

The summary for the Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors Biostatistics Research Center (U01 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors Biostatistics Research Center (U01 Clinical Trial Not Allowed): This Notice of Funding Opportunity (NOFO) invites applications for a Biostatistics Research Center (BRC) to participate in a clinical consortium to better understand the neurocognitive impact of new onset type 1 diabetes (T1D) in pre-pubertal children. A separate RFA (RFA-DK-23-010 ) invites Clinical Centers (CCs) to establish a diverse cohort of pre-pubertal children newly diagnosed with T1D and will longitudinally evaluate disease-related perturbations in neurocognitive function, as well as identify potential clinical, developmental, and/or environmental factors associated with neurocognitive function in T1D. The PI(s) of the BRC and the PIs from each of the CCs selected via RFA-DK-23-010 will form a cooperative research consortium in conjunction with NIDDK to design and implement a uniform protocol across approximately 10 CCs and the BRC. Findings from this observational study are expected to advance our understanding of the impact of T1D on the developing brain and identify risk and protective factors associated with neurocognitive functioning to ultimately inform on effective strategies to decrease adverse neurodevelopmental outcomes and long-term neurocognitive sequelae of T1D.

Federal Grant Title:	Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors Biostatistics Research Center (U01 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Food and Nutrition Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DK-23-009
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.847
CFDA Descriptions:	Information not provided
Current Application Deadline:	October 26th, 2023
Original Application Deadline:	October 26th, 2023
Posted Date:	May 15th, 2023
Creation Date:	May 15th, 2023
Archive Date:	December 1st, 2023
Total Program Funding:
Maximum Federal Grant Award:	$1,200,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	May 16th, 2023

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-23-009.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required); • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial...; • Adaptation of Diabetes Control Technologies for Older Adults with T1D (R01 Clinical Trial...; • Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortiu...; • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes; • Molecular Therapy Core Centers; • Pilot and Feasibility Program in Human Islet Biology
More Grants from the National Institutes of Health: • Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required); • Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans...; • Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required); • NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional); • NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)